{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:14:54Z","timestamp":1792642494426,"version":"4.5.0"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013092","name":"Science and Technology Planning Project of Fuzhou","doi-asserted-by":"publisher","award":["2021CC28\u201312"],"award-info":[{"award-number":["2021CC28\u201312"]}],"id":[{"id":"10.13039\/501100013092","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.biopha.2023.115820","type":"journal-article","created":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T23:23:58Z","timestamp":1699226638000},"page":"115820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Venetoclax in adult acute myeloid leukemia"],"prefix":"10.1016","volume":"168","author":[{"given":"Mengci","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youshan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caixia","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6535-2779","authenticated-orcid":false,"given":"Jie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.115820_bib1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.115820_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194756","article-title":"Updates on the management of acute myeloid leukemia","volume":"14","author":"Huerga-Dominguez","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2023.115820_bib3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2023.115820_bib4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41408-022-00770-x","article-title":"Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis","volume":"12","author":"Kwag","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.biopha.2023.115820_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.584974","article-title":"Targeting Bcl-2 proteins in acute myeloid leukemia","volume":"10","author":"Wei","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2023.115820_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11523-020-00711-3","article-title":"Targeting apoptosis in acute myeloid leukemia: current status and future directions of bcl-2 inhibition with venetoclax and beyond","volume":"15","author":"Choi","year":"2020","journal-title":"Target. Oncol."},{"key":"10.1016\/j.biopha.2023.115820_bib7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell stem Cell"},{"key":"10.1016\/j.biopha.2023.115820_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184557","article-title":"Targeting autophagy triggers apoptosis and complements the action of venetoclax in chronic lymphocytic leukemia cells","volume":"13","author":"Avsec","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2023.115820_bib9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","article-title":"BCL-2 family proteins: changing partners in the dance towards death","volume":"25","author":"Kale","year":"2018","journal-title":"Cell death Differ."},{"key":"10.1016\/j.biopha.2023.115820_bib10","doi-asserted-by":"crossref","first-page":"14040","DOI":"10.1002\/jcp.28091","article-title":"The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML","volume":"234","author":"Nguyen","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.biopha.2023.115820_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2019.01.011","article-title":"Systematic dissection of the metabolic-apoptotic interface in AML reveals heme biosynthesis to be a regulator of drug sensitivity","volume":"29","author":"Lin","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.biopha.2023.115820_bib12","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase ii study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2023.115820_bib13","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2023.115820_bib14","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/cncr.34608","article-title":"AVALON: the Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed\/refractory patients with acute myeloid leukemia","volume":"129","author":"Todisco","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2023.115820_bib15","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.115820_bib16","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.21.02823","article-title":"Phase II study of venetoclax added to cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia","volume":"40","author":"Kadia","year":"2022","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.115820_bib17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10238-021-00784-y","article-title":"Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis","volume":"23","author":"Qin","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.biopha.2023.115820_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac486","article-title":"Incidence of invasive fungal infections in patients with previously untreated acute myeloid leukemia receiving venetoclax and azacitidine","volume":"9","author":"Zhang","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.biopha.2023.115820_bib19","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","article-title":"Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial","volume":"9","author":"Wang","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.biopha.2023.115820_bib20","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ajh.26601","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia","volume":"97","author":"DiNardo","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.biopha.2023.115820_bib21","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","article-title":"Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial","volume":"8","author":"Kadia","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.biopha.2023.115820_bib22","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.22.00602","article-title":"Venetoclax plus gilteritinib for FLT3-mutated relapsed\/refractory acute myeloid leukemia","volume":"40","author":"Daver","year":"2022","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.115820_bib23","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1002\/cncr.33814","article-title":"Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: a propensity score-matched analysis","volume":"127","author":"Maiti","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2023.115820_bib24","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","article-title":"Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML","volume":"5","author":"Stahl","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.biopha.2023.115820_bib25","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2023.115820_bib26","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1172\/JCI97117","article-title":"Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates","volume":"128","author":"Gu","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.biopha.2023.115820_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221810040","article-title":"Significance of NPM1 Gene Mutations in AML","volume":"22","author":"Hindley","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2023.115820_bib28","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1200\/JCO.2009.25.1496","article-title":"Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study","volume":"28","author":"Becker","year":"2010","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.115820_bib29","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3324\/haematol.2014.104133","article-title":"Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse","volume":"99","author":"Hubmann","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2023.115820_bib30","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1182\/blood-2007-08-109090","article-title":"The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia","volume":"111","author":"Gale","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.115820_bib31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.115820_bib32","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.20.00572","article-title":"Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy","volume":"38","author":"Chua","year":"2020","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.115820_bib33","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.115820_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2018.08.005","article-title":"Mutant NPM1 maintains the leukemic state through HOX expression","volume":"34","author":"Brunetti","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2023.115820_bib35","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/leu.2016.222","article-title":"HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia","volume":"31","author":"Kontro","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2023.115820_bib36","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1182\/bloodadvances.2019001267","article-title":"Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens","volume":"4","author":"Lachowiez","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.biopha.2023.115820_bib37","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/bjh.16722","article-title":"Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia","volume":"192","author":"Tiong","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biopha.2023.115820_bib38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrclinonc.2017.151","article-title":"Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others","volume":"15","author":"Sabapathy","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.115820_bib39","doi-asserted-by":"crossref","first-page":"a000919","DOI":"10.1101\/cshperspect.a000919","article-title":"The tumor suppressor p53: from structures to drug discovery","volume":"2","author":"Joerger","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.biopha.2023.115820_bib40","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2023.115820_bib41","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood.2020010167","article-title":"Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias","volume":"137","author":"Thijssen","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.115820_bib42","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1002\/cncr.33675","article-title":"Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy","volume":"127","author":"Venugopal","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2023.115820_bib43","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/cncr.33689","article-title":"Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax","volume":"127","author":"Kim","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2023.115820_bib44","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-021-01148-5","article-title":"Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia","volume":"14","author":"Aitken","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2023.115820_bib45","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1158\/2159-8290.CD-22-0332","article-title":"TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions","volume":"12","author":"Daver","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2023.115820_bib46","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-021-00495-3","article-title":"FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm","volume":"11","author":"Daver","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.biopha.2023.115820_bib47","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1080\/1042819031000067503","article-title":"Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia","volume":"44","author":"Kottaridis","year":"2003","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.biopha.2023.115820_bib48","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2023.115820_bib49","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/ajh.25198","article-title":"Sorafenib combined with 5-azacytidine in older patients with untreated FLT3-ITD mutated acute myeloid leukemia","volume":"93","author":"Ohanian","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.biopha.2023.115820_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2019.10.018","article-title":"A phase ii study of midostaurin and 5-azacitidine for untreated elderly and unfit patients with FLT3 wild-type acute myelogenous leukemia","volume":"20","author":"Tomlinson","year":"2020","journal-title":"Clin. Lymphoma, Myeloma Leuk."},{"key":"10.1016\/j.biopha.2023.115820_bib51","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41408-022-00670-0","article-title":"Hypomethylating agent and venetoclax with FLT3 inhibitor \"triplet\" therapy in older\/unfit patients with FLT3 mutated AML","volume":"12","author":"Yilmaz","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.biopha.2023.115820_bib52","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia","volume":"21","author":"Chan","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2023.115820_bib53","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2023.115820_bib54","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.115820_bib55","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/ajh.25978","article-title":"Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients","volume":"95","author":"Morsia","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.biopha.2023.115820_bib56","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2023.115820_bib57","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.26039","article-title":"Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study","volume":"96","author":"Pollyea","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.biopha.2023.115820_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143456","article-title":"Targeting acute myeloid leukemia with venetoclax; biomarkers for sensitivity and rationale for venetoclax-based combination therapies","volume":"14","author":"Griffioen","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2023.115820_bib59","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00277-019-03719-6","article-title":"Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study","volume":"98","author":"Ram","year":"2019","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.biopha.2023.115820_bib60","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2023.115820_bib61","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.stem.2015.06.002","article-title":"Runx1 deficiency decreases ribosome biogenesis and confers stress resistance to hematopoietic stem and progenitor cells","volume":"17","author":"Cai","year":"2015","journal-title":"Cell stem Cell"},{"key":"10.1016\/j.biopha.2023.115820_bib62","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.biopha.2023.115820_bib63","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00277-020-03911-z","article-title":"Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax","volume":"99","author":"Wang","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.biopha.2023.115820_bib64","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2022-165464","article-title":"Reduced venetoclax exposition to seven days of azacitidine is efficient in treatment-na\u00efve patients with acute myeloid leukemia","volume":"140","author":"Willekens","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.115820_bib65","unstructured":"B. May, Reduced Venetoclax Exposure With Azacitidine Appears Feasible in Treatment-Na\u00efve AML, American society of hematology. (2023)."},{"key":"10.1016\/j.biopha.2023.115820_bib66","doi-asserted-by":"crossref","first-page":"9005","DOI":"10.1182\/blood-2022-162918","article-title":"A phase ii study of azacitidine plus venetoclax as maintenance therapy in acute myeloid leukemia: durable responses with longer term follow-up","volume":"140","author":"Bazinet","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.115820_bib67","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00277-023-05102-y","article-title":"Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia","volume":"102","author":"Aiba","year":"2023","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.biopha.2023.115820_bib68","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2023020649","article-title":"Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia","author":"Senapati","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.115820_bib69","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1182\/blood-2022-169509","article-title":"ELN risk stratification is not predictive of outcomes for treatment-na\u00efve patients with acute myeloid leukemia treated with venetoclax and azacitidine","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.115820_bib70","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11060463","article-title":"Review of venetoclax in CLL, AML and multiple myeloma","volume":"11","author":"Lasica","year":"2021","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.biopha.2023.115820_bib71","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3389\/fonc.2018.00645","article-title":"BCL2-family dysregulation in b-cell malignancies: from gene expression regulation to a targeted therapy biomarker","volume":"8","author":"Tessoulin","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2023.115820_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13225608","article-title":"Venetoclax in acute myeloid leukemia: molecular basis, evidences for preclinical and clinical efficacy and strategies to target resistance","volume":"13","author":"Garciaz","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2023.115820_bib73","doi-asserted-by":"crossref","first-page":"380","DOI":"10.20517\/cdr.2021.125","article-title":"Venetoclax resistance: mechanistic insights and future strategies","volume":"5","author":"Ong","year":"2022","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.biopha.2023.115820_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2020000154","article-title":"Therapeutic development and current uses of BCL-2 inhibition","volume":"2020","author":"Roberts","year":"2020","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.biopha.2023.115820_bib75","first-page":"1247","article-title":"Pro-apoptotic protein bim in lung cancer","volume":"41","author":"Deng Wei","year":"2014","journal-title":"Cancer Res Prev. Treat."},{"key":"10.1016\/j.biopha.2023.115820_bib76","article-title":"Biomarkers predicting venetoclax sensitivity and strategies for venetoclax combination treatment","volume":"132","author":"Zhang","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.115820_bib77","doi-asserted-by":"crossref","first-page":"E202","DOI":"10.1002\/ajh.25146","article-title":"Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia","volume":"93","author":"Chyla","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.biopha.2023.115820_bib78","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1182\/blood.2019004757","article-title":"BCL-2 inhibition and AML: can we best Darwin?","volume":"135","author":"Michaelis","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2023.115820_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.562558","article-title":"Venetoclax-based combinations in acute myeloid leukemia: current evidence and future directions","volume":"10","author":"Samra","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2023.115820_bib80","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1158\/1078-0432.CCR-19-2339","article-title":"Improving response to FLT3 inhibitors-BCL2 the rescue?","volume":"25","author":"Perl","year":"2019","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.biopha.2023.115820_bib81","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/oncolo\/oyac135","article-title":"Venetoclax and hypomethylating agents as first-line treatment in newly diagnosed patients with AML in a predominately community setting in the US","volume":"27","author":"Vachhani","year":"2022","journal-title":"oncologist"},{"key":"10.1016\/j.biopha.2023.115820_bib82","doi-asserted-by":"crossref","first-page":"5613","DOI":"10.2147\/CMAR.S316561","article-title":"Efficacy of venetoclax combined with decitabine-based treatment for heavily pre-treated relapsed or refractory AML patients in a real-world setting","volume":"13","author":"Tong","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.biopha.2023.115820_bib83","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/joim.13581","article-title":"Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia","volume":"293","author":"Weng","year":"2023","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.biopha.2023.115820_bib84","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.3324\/haematol.2022.281214","article-title":"Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naive acute myeloid leukemia","volume":"107","author":"Gangat","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2023.115820_bib85","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14082025","article-title":"Azacitidine plus venetoclax for the treatment of relapsed and newly diagnosed acute myeloid leukemia patients","volume":"14","author":"Garciaz","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2023.115820_bib86","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s00277-022-04883-y","article-title":"Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis","volume":"101","author":"Wolach","year":"2022","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.biopha.2023.115820_bib87","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/ajh.26724","article-title":"Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia","volume":"97","author":"Venugopal","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.biopha.2023.115820_bib88","doi-asserted-by":"crossref","DOI":"10.4084\/MJHID.2022.080","article-title":"The Growing Role of the BH3 mimetic drug venetoclax in the therapy of acute myeloid leukemia","volume":"14","author":"Pelosi","year":"2022","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"10.1016\/j.biopha.2023.115820_bib89","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","article-title":"Impact of venetoclax and azacitidine in treatment-naive patients with acute myeloid leukemia and IDH1\/2 mutations","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.biopha.2023.115820_bib90","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26731","article-title":"Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes","volume":"97","author":"Rivera","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.biopha.2023.115820_bib91","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1080\/10428194.2022.2116934","article-title":"Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)","volume":"63","author":"Ball","year":"2022","journal-title":"Leuk. Lymphoma"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223016189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223016189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:41:53Z","timestamp":1779918113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223016189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":91,"alternative-id":["S0753332223016189"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115820","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Venetoclax in adult acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115820","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115820"}}